Health & Wellness

Atlantic Health System Cancer Care First in World to Begin Clinical Trial of Novel Virus-Based Immunotherapy for Late-Stage Melanoma; First Patient Enrolled

5e81572f1ea7b6a75870_Screen_Shot_2017-08-04_at_8.54.24_AM.jpg
The clinical trial is being led locally by Eric D. Whitman, MD, FACS. Credits: Atlantic Health System
5e81572f1ea7b6a75870_Screen_Shot_2017-08-04_at_8.54.24_AM.jpg

MORRISTWON, NJ - Atlantic Health System Cancer Care is the first oncology institution in the world to sign on to, and to enroll the first patient in, a multi-center Phase IIa clinical trial of OBP-301 (Telomelysin®), a virus-based immunotherapy for late-stage melanoma that has not responded to other treatments. 

This leading-edge experimental therapy, which is under development by Japanese biotechnology company Oncolys BioPharma, uses the common cold virus to modify a gene that can selectively replicate in, and destroy, cancer cells. The study protocol was approved by the U.S. Food and Drug Administration (FDA) in June.

The clinical trial is being led locally by Eric D. Whitman, MD, FACS, medical director of Atlantic Health System Cancer Care and director of the Carol G. Simon Cancer Center’s Atlantic Melanoma Center at Overlook Medical Center and Morristown Medical Center.

Sign Up for E-News

“This targeted immunotherapy holds great promise for improving survival rates in patients with unresectable and metastatic melanoma,” said Whitman.  “We are proud to have been chosen as the first site for this leading edge clinical trial, and happy to be able to offer a wide range of the latest established and experimental treatments to our patients.”

Melanoma, the most serious form of skin cancer, affects more than 50,000 people each year. Although the chances of having melanoma increase with age, the number of cases among young adults is rising every year. Melanoma can have serious health consequences and may even be fatal.

The OBP-301 trial is a multi-center, Phase IIa study to evaluate how melanoma tumors respond to injection of this drug in patients with Stage III and Stage IV melanoma -- that is, to determine how much the drug shrinks or destroys tumors after it is injected into them.  The study, which will also look at potential side effects, is “open label,” meaning that all participants in the study will receive OBP-301. 

OBP-301 is a type of virus known as an adenovirus. Adenoviruses are common in nature and when they multiply in normal human cells they may cause infections that result in symptoms like those of the common cold or the flu.  OBP-301 has been genetically changed from the original virus to reproduce in target cancer cells that are emitting a certain signal. As a result of this reproduction, OBP-301 is believed to burst and kill tumor cells.

Study participants will receive multiple injections into their tumors over a period of several weeks.  Blood tests will be done to evaluate the level of virus in patients’ systems, and for immune response monitoring. Dr. Whitman and colleagues will also evaluate how long it takes to get a response and how long responses last, as well as overall survival and progression-free survival rates.

In preclinical studies, Oncolys demonstrated OBP-301’s anti-tumor activity in various types of cancer cells.  A Phase I clinical trial in the U.S. demonstrated the drug’s safety, and showed that it shrank tumors in a majority of study participants, who had a variety of solid tumors.  Additional studies of the drug have been completed, or are underway, in Japan, Korea and Taiwan.

The Atlantic Melanoma Center, a clinical and research center of excellence, is an internationally-recognized program. The center’s multidisciplinary approach-- combining the expertise of board-certified surgeons, medical oncologists, pathologists, radiation oncologists and nurses – treats all forms of melanoma, including those in the skin, mucous membranes and eyes.  Patients receive the latest medical treatments, and when needed, melanoma surgery is also available. 

For more information on the OBP-301 clinical trial or other studies, please call the Atlantic Melanoma Center at 973-971-7111.  

TAP Into Another Town's News:

You May Also Be Interested In

Sign Up for E-News

Summit

Upcoming Events

Carousel_image_92eaadab4fea5d764092_edc2dcd4802a1c409d7c_screen_shot_2018-04-03_at_1.15.57_pm

Sun, June 24, 8:00 AM

Summit Summer Farmers Market, Summit

Summit Farmers Market

Community Calendar Food & Drink Green Health & Wellness

Carousel_image_5e177eaae57739064cd4_397f63ad2fb50392a776_29178074_2107642336134787_2638697507160326144_n

Sun, June 24, 11:00 AM

Totowa

MakerFest 2018

Summit Police Blotter

May 29, 2018

5/15 - Sean M. Reidy, 52, of Summit was arrested on a contempt of court warrant out of Summit. Mr. Reidy was able to post bail and released with a pending court date.

5/18 - At 1615 hours a report was taken for a theft from a Springfield Avenue business. The incident occurred at approximately 1031 hours when a white female entered the business and removed a blue Ramy Brook Blouse from a rack.

Bridges Outreach: Miracles in Manhattan

June 17, 2018

Bridges Outreach: Miracles in Manhattan (and elsewhere)

My good friend Joan Olszewski reached out to me the other day to tell me the Friday, June 8, Bridges Outreach run to Manhattan needed volunteers, “Let’s go,” she said.  The lunches were provided by Pimco, a dedicated corporate sponsor of Bridges, so all we needed were some bodies and the love necessary to offer food ...

Video: Point View's Petrides Looks at Media M&As, Fed's Hike Strategy

Point View Wealth Management's Managing Director and Portfolio Manager, John Petrides, live on FOX Business AM discussing M&A in the media industry and the Fed's path to four hikes in 2018:

ptview.com/medias/tv-radio

​​​​​​For more than 25 years, Point View Wealth Management, Inc. has been working with families in Summit and beyond, providing customized portfolio ...

Maximizing Your Portfolio’s Returns -- Beware the Taxman

The old adage in the investment world is that it is not what you make, but what you keep that counts.  Investors often overlook the ultimate deflator of portfolio returns – the taxman. An astute global asset allocation should be the number one priority for investors.  However, there are preferred ways to distribute this asset allocation over the spectrum of taxable and ...

AtlantiCast

AtlantiCast: Episode 16

Summer is in the air, and the latest episode of AtlantiCast is ready to help you enjoy some fun outdoors while staying safe! This week’s episode opens with tips for sunscreen usage from Atlantic Health System’s Chief Medical and Academic Officer, Dr. Jan Schwarz-Miller. You’ll also learn about how Atlantic Health System is advancing the future of health care through ...

Video: In The Zone with Christa Anderson

A must watch for anyone considering renovations, here is a recent interview that I conducted -- on my HomeTowne TV Show called “Are You Ready for Life?” -- with Christa Anderson, City of Summit Zoning Officer, to discuss the nuances within the variance process.

I asked Christa to shed some insight into the approval process, explain why it’s necessary, and ...

Hello, Neighbors

Hi, Summit families!

My name is Betsy Stoeber and I’ve been the owner and director at the specialized learning center Brain Balance of Summit since 2011. I first encountered Brain Balance the year before we opened as a parent. My own son participated in our innovative program at the center in Norwalk, CT, to address a number of learning challenges.

Traveling there three times per week ...